Tag: Leukemia and Lymphoma

Durable efficacy with fixed‐duration BTKi and venetoclax for CLL

AI SummaryThis article discusses the durable efficacy of fixed-duration Bruton’s Tyrosine Kinase inhibitors (BTKi) and venetoclax for Chronic Lymphocytic Leukemia (CLL). The study highlights the long-lasting effectiveness of this treatment combination for CLL patients. The findings suggest promising results in managing CLL with a set treatment duration using BTKi and venetoclax.Cancer, Volume 130, Issue 19,… Continue reading Durable efficacy with fixed‐duration BTKi and venetoclax for CLL

Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

AI SummaryThis clinical practice guideline focuses on the diagnosis, treatment, and follow-up of human immunodeficiency virus-associated lymphomas, specifically non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Despite a decrease in the incidence of HIV-associated NHL with the introduction of combination antiretroviral therapy (ART), NHL remains a common type of cancer in individuals living with HIV. Incidences… Continue reading Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Odronextamab against relapsed or refractory follicular lymphoma

AI SummaryThe article discusses the use of Odronextamab in patients with relapsed or refractory follicular lymphoma, showing high complete response rates and manageable safety. The study highlights the importance of achieving complete response for better overall survival and progression-free survival. The median time to first response was 2.7 months.T.M. Kim et al (August 6th issue)1… Continue reading Odronextamab against relapsed or refractory follicular lymphoma

Blood stem cell breakthrough could transform bone marrow transplants

AI SummaryResearchers have achieved a groundbreaking feat in creating blood stem cells that closely mimic those found in the human body. This breakthrough holds promise for personalized treatments for children suffering from leukemia and bone marrow failure disorders. The development could potentially transform the field of bone marrow transplants.Researchers have made a world first breakthrough… Continue reading Blood stem cell breakthrough could transform bone marrow transplants

Editors’ Picks, August 2024: ‘Colon Age’ Screening Recs, Stress From Violence, and More 

AI SummaryThis article highlights the Editors’ Picks from August 2024 for the American Association for Cancer Research (AACR). The selections include topics such as a new metric called “Colon Age” for early-onset colorectal cancer screening, the relationship between exposure to neighborhood violence and glucocorticoid receptor signaling in lung tumors, and the development of a CD33-targeting… Continue reading Editors’ Picks, August 2024: ‘Colon Age’ Screening Recs, Stress From Violence, and More 

[ASAP] A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma

AI SummaryThis article discusses a new mitochondria-targeting SIRT3 inhibitor that shows activity against Diffuse Large B Cell Lymphoma. The inhibitor specifically targets SIRT3, a protein involved in metabolism and cell survival, making it a potential therapeutic option for this type of lymphoma. This research holds promise for developing targeted treatments for cancer that can specifically… Continue reading [ASAP] A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma